Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals

A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals Opinion EDITORIAL A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals Arturo Casadevall, MD, PhD; Michael J. Joyner, MD; Liise-Anne Pirofski, MD Convalescent plasma for the treatment of infectious diseases group compared with the control group, and clinical has been used since the early 20th century and was associ- improvement at 28 days occurred in 27 patients (51.9%) in the intervention group vs 22 patients (43.1%) in the control ated with reduced mortality during the 1918 influenza, 2003 2 3 SARS, and 2009 influenza H1N1 pandemics. However, most group (difference, 8.8%; 95% CI, −10.4% to 28%; hazard published studies of these ratio, 1.40 [95% CI, 0.79-2.49]; P = .26). diseases were case series and In analyses stratified by disease severity, among patients Related article page 460 and retrospective comparisons of with severe disease (23 in the convalescent plasma group and JAMA Patient Page page 524 treated and nontreated indi- 22 in the control group), time to clinical improvement within viduals. Consistent with this, several uncontrolled case series 28 days was 4.94 days shorter (95% CI, −9.33 to −0.54 days) of convalescent plasma use in patients with coronavirus dis- in the intervention group compared with the control group, 4-6 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals

JAMA , Volume 324 (5) – Aug 4, 2020

Loading next page...
 
/lp/american-medical-association/a-randomized-trial-of-convalescent-plasma-for-covid-19-potentially-3jfgovxs1E
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2020.10218
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals Arturo Casadevall, MD, PhD; Michael J. Joyner, MD; Liise-Anne Pirofski, MD Convalescent plasma for the treatment of infectious diseases group compared with the control group, and clinical has been used since the early 20th century and was associ- improvement at 28 days occurred in 27 patients (51.9%) in the intervention group vs 22 patients (43.1%) in the control ated with reduced mortality during the 1918 influenza, 2003 2 3 SARS, and 2009 influenza H1N1 pandemics. However, most group (difference, 8.8%; 95% CI, −10.4% to 28%; hazard published studies of these ratio, 1.40 [95% CI, 0.79-2.49]; P = .26). diseases were case series and In analyses stratified by disease severity, among patients Related article page 460 and retrospective comparisons of with severe disease (23 in the convalescent plasma group and JAMA Patient Page page 524 treated and nontreated indi- 22 in the control group), time to clinical improvement within viduals. Consistent with this, several uncontrolled case series 28 days was 4.94 days shorter (95% CI, −9.33 to −0.54 days) of convalescent plasma use in patients with coronavirus dis- in the intervention group compared with the control group, 4-6

Journal

JAMAAmerican Medical Association

Published: Aug 4, 2020

References